| Literature DB >> 32437660 |
Hiroyuki Katayama1, Hiroshi Hama1, Koji Nagasawa2, Hiroshi Kurokawa1, Mayu Sugiyama1, Ryoko Ando1, Masaaki Funata2, Nobuyo Yoshida3, Misaki Homma4, Takanori Nishimura2, Megumu Takahashi5, Yoko Ishida5, Hiroyuki Hioki5, Yoshiyuki Tsujihata6, Atsushi Miyawaki7.
Abstract
Dysfunctional mitochondria accumulate in many human diseases. Accordingly, mitophagy, which removes these mitochondria through lysosomal degradation, is attracting broad attention. Due to uncertainties in the operational principles of conventional mitophagy probes, however, the specificity and quantitativeness of their readouts are disputable. Thorough investigation of the behaviors and fates of fluorescent proteins inside and outside lysosomes enabled us to develop an indicator for mitophagy, mito-SRAI. Through strict control of its mitochondrial targeting, we were able to monitor mitophagy in fixed biological samples more reproducibly than before. Large-scale image-based high-throughput screening led to the discovery of a hit compound that induces selective mitophagy of damaged mitochondria. In a mouse model of Parkinsons disease, we found that dopaminergic neurons selectively failed to execute mitophagy that promoted their survival within lesions. These results show that mito-SRAI is an essential tool for quantitative studies of mitochondrial quality control.Entities:
Keywords: FRET; Parkinsons disease; autophagy; fluorescent protein; high-throughput screening; lysosome; mitochondria; mitophagy
Mesh:
Substances:
Year: 2020 PMID: 32437660 DOI: 10.1016/j.cell.2020.04.025
Source DB: PubMed Journal: Cell ISSN: 0092-8674 Impact factor: 41.582